CARLSBAD, Calif., June 04, 2019 (GLOBE NEWSWIRE)
-- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich
Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the
world leader in the science, development, and commercialization of
cannabinoid prescription medicines, today announced that Stephen
Schultz, GW’s Vice President of Investor Relations, will present at
the 40th Annual Goldman Sachs Global Healthcare
Conference on Tuesday, June 11, 2019 at 11:20 a.m. PDT at the
Terranea Resort in Rancho Palos Verdes,
California.
A live audio webcast of the presentation will be available through GW’s corporate website at www.gwpharm.com on the Investors section under Events & Presentations. A replay will be available soon after the live presentation.
About GW Pharmaceuticals plc and
Greenwich Biosciences, Inc.
Founded in 1998, GW is a biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
its proprietary cannabinoid product platform in a broad range of
disease areas. GW, along with its U.S. subsidiary Greenwich
Biosciences, has received U.S. FDA approval for EPIDIOLEX
(cannabidiol) oral solution for the treatment of seizures
associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in
patients two years of age or older and which is now available by
prescription in the U.S. The Company has submitted a regulatory
application in Europe for the adjunctive treatment of seizures
associated with LGS and Dravet syndrome. The company continues to
evaluate EPIDIOLEX in additional rare epilepsy conditions including
Tuberous Sclerosis Complex (TSC) and Rett syndrome. GW
commercialized the world’s first plant-derived cannabinoid
prescription drug, Sativex® (nabiximols), which is approved for the
treatment of spasticity due to multiple sclerosis in numerous
countries outside the United States and for which the company is
now planning a U.S. Phase 3 trial. The Company has a deep pipeline
of additional cannabinoid product candidates which includes
compounds in Phase 1 and 2 trials for epilepsy, glioblastoma, and
schizophrenia. For further information, please visit www.gwpharm.com.
Enquiries:
| GW Pharmaceuticals plc | |
| Stephen Schultz, VP Investor Relations (U.S.) | 917 280 2424 / 401 500 6570 |